Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin M Balko

Showing results (71-80 of 174) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2011
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistanceTodd W Miller, Justin M Balko, Zara Ghazoui, et al.
Oncoimmunology|June 7, 2018
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2Na Luo, Luigi Formisano, Paula I Gonzalez-Ericsson, et al.
Journal of Visualized Experiments : Jove|April 12, 2021
Automated Dissection Protocol for Tumor Enrichment in Low Tumor Content TissuesCharles A Havnar, Oliver Zill, Jeff Eastham, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 20, 2011
The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epitheliumJustin M Balko, Todd W Miller, Meghan M Morrison, et al.
Biomaterials|May 7, 2026
A molecularly defined polymeric platform for environmentally responsive activation of STING to enhance cancer immunotherapyJacob A Schulman, Karan Arora, Alexander J Kwiatkowski, et al.
Cancer Research|May 2, 2013
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signalingChristian D Young, Adam D Pfefferle, Philip Owens, et al.
NPJ Breast Cancer|June 21, 2025
A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancerJessica Mezzanotte-Sharpe, Brandie C Taylor, Paula I Gonzalez-Ericsson, et al.
Oncoimmunology|May 17, 2017
Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profilingPeter J Siska, Romany A N Johnpulle, Alice Zhou, et al.
The Lancet. Oncology|November 17, 2018
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance studyJoe-Elie Salem, Ali Manouchehri, Melissa Moey, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 14, 2013
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesAriella B Hanker, Adam D Pfefferle, Justin M Balko, et al.
Pageof 18

Showing results (71-80 of 174) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2011
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistanceTodd W Miller, Justin M Balko, Zara Ghazoui, et al.
Oncoimmunology|June 7, 2018
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2Na Luo, Luigi Formisano, Paula I Gonzalez-Ericsson, et al.
Journal of Visualized Experiments : Jove|April 12, 2021
Automated Dissection Protocol for Tumor Enrichment in Low Tumor Content TissuesCharles A Havnar, Oliver Zill, Jeff Eastham, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 20, 2011
The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epitheliumJustin M Balko, Todd W Miller, Meghan M Morrison, et al.
Biomaterials|May 7, 2026
A molecularly defined polymeric platform for environmentally responsive activation of STING to enhance cancer immunotherapyJacob A Schulman, Karan Arora, Alexander J Kwiatkowski, et al.
Cancer Research|May 2, 2013
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signalingChristian D Young, Adam D Pfefferle, Philip Owens, et al.
NPJ Breast Cancer|June 21, 2025
A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancerJessica Mezzanotte-Sharpe, Brandie C Taylor, Paula I Gonzalez-Ericsson, et al.
Oncoimmunology|May 17, 2017
Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profilingPeter J Siska, Romany A N Johnpulle, Alice Zhou, et al.
The Lancet. Oncology|November 17, 2018
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance studyJoe-Elie Salem, Ali Manouchehri, Melissa Moey, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 14, 2013
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesAriella B Hanker, Adam D Pfefferle, Justin M Balko, et al.
Pageof 18